You are here

Home » Content

ROLE OF OVARY AND ADRENAL GLANDS IN HYPERANDROGENEMIA IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 2004

Key Words:

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Ovary is the main source of the hypcrandrogenism in polycystic ovary syndrome (PCOS). Adrenal glands may also be involved in the palhogencsİs of the development of PCOS. To inves-tigate thİs possibiiİty and to find out if buserelin test is able to dİslinguish PCOS patients from the patients with idiopalic hirsutisnı (İH), 29 womcn wilh PCOS, 21 women with IH, and 20 control subjects (CS) were subjectcd to ACTH and buserciin tests. Basal and stimulated dehydroepiandrosterone sulfate (DHEA-S) and slimulated cortisol (F) leveis at'ter ACTH administration weıe sigııificantly higher in PCOS group than in IH and CS groups (p<0.0001 and p<0.05, rcspectively). PCOS patients also possessed sigııificantly higher basaî and stimulated 17-hydroxyprogeslerone (17-OH P) leveis, ineluding the peak Icvels (p<0.02), during buserelin tcstİng when compared vvith IH patients and CS. There was no sig-nificant corrclalion between the ACTH stimulated and the buserelin stimulated peak 17-OH P value.s (r=0.157, p>0.05). In conelusion, sigııificantly higher basal and ACTH stimuiatcd leveis of F and DHEA-S in PCOS compared vvith controls and patients with İH, rcflect that adrenal Iıyperaetivity plays a role in hyperandrogencmia seen in PCOS. The lack of the correlation betwcen ACTH and buserelin stimulated 17-OH P leveis makes it difficull to say that adrenal hypcractivity seen in PCOS is the result of the dysrcgulation of cylochrome P450cl7-ct enzyme. Buserelin test could dislinguish at least some of the patients with PCOS from the other patients prcsenliııg witlı the coramon symptoms of hyperandrogenemia.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-role-ovary-and-adrenal-glands-hyperandrogenemia-patients-polycystic-ovary-syndrome.pdf
  • 1
28-36
  • English

REFERENCES

References: 

1. Lewis V: Polycystic ovary syndrome- A diagnostic challenge. Obstet Gynecol Clin North Am 2001; 28: 1.
2. Kandarakis ED, Dunaif A: New perspeetives in polycystic ovary syndrome. Trends Endocrinol Metal} 1996; 7: 267.
3. Martikainen H, Salmela P, Nuojua-Hullunen S, ct al: Adrenal steroidogenesis is related to insulin in hypcrandro-geııic womeıı. Fertil Steril 1996; 66: 564.
4. Turner El, VVatson MJ, Perry LA, White MC: Investiga-tion of adrenal funetion in women vvith oligomcnorrhoea and hirsutism (clinical PCOS) from the north-east of England using an adrenal stimulation test. Clin Enciocriıı-ol (Oxford) 1992; 36: 389.
5. Rosenfıeld RL, Barnes RB, Cara JF, Lucky AW: Dysregulation of cytochrome P450cl7-ct as the cause of poly-cyslic ovarian syndrome. Fertil Steril 1990, 53: 785.
6. Miller WL: Molecular biology of steroid hormone syn-thesis. EndocrRev 1988; 9: 295.
7. Takayama K, Fukaya T, Sasano H, et al: Immunolıisto-chemical study of steroidogenesis and celi proliferation in polycystic ovarian syndrome. Hum Reprod 1996; 11: 1387.
8. Ehrmann DA, Rosenfield RL, Barnes RB, Brigeli DF, Sheikh Z: Detection of funcîional ovarian hyperandrogenism in women vvith androgen excess. N Engl J Mcd 1992; 327: 157.
9. Bames RB, Rosenfield RL, Burstcin S, Ehrmann DA: Pimi tary-ovari an responses to nal'arelin testing in the polycystic ovary syndrome. N Engl J Mcd 1989; 320: 559.
10. Azziz R, Riumastcr RS, Fox LM, Bradley EL Jr, Potter HD, Boots LR: Role of the ovary in the adrenal androgen excess of hypcrandrogenic vvomen. Fertil Steril 1998; 69: 85i.
11. Azziz R, Bradley EL Jr, Potter HD, Boots LR: Adrenal adrogen excess in vvomen: lack of a role for 17-hydroxy-lase and 17,20 lyase dysregulation. J Clin Endocrinol Metab 1995; 80: 400.
Role of Ovary and Adrenal Glands in Hyperandrogenemia in Patients \vith Polycystic Ovary Syndrome
12. Ehrmann DA, Barnes RB, Rosenfield RL: Polycystic ovary syndrome as a form of funclİonal ovarian hyperandrogenism due to dysregulation of androgen secrelion. EndocrRev 1995; 16; 322.
13. Şahin Y, Kelcştimur F: 17-fıydroxyprogesterone re-sponse to buserelin testing in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1993; 39: 151.
14. Ibanez L, Potau N, Zampolli M, et al: Source localizaüon of androgen excess in adolescent giriş. J Clin Endocrinol Metab 1994; 79: 1778.
15. VVhite D, Leigh A, VViison C, Donaldson A, Franks S: Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory vvomen vvith polycystic ovary syndrome. Clin Endocrinol (Oxf) 1995; 42: 475.
16. Azziz R, Rafi A, Smith BR, Bradley EL Jr, Zacur HA: On the origin of the elevated 17-hydroxyprogesterone leveis after adrenal stimulation in hyperandrogenism. J Clin Endocrinol Metab 1990; 70: 431,
17. Şahin Y, Kelcştimur F: 17-hydroxyprogesterone responses to gonadotrophin-releasing hormone agonist buserelin and adrenocorticotrophin in polycystic ovary syndrome: investigation of adrenal and ovarian cytochrome P450cl7-adysregulation. Hum Reprod 1997; 12: 910.
18. Hatch R, Rosenfield RL, Kim MH, Tredvvay D: Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981;140:815.
19. Chetkovvski RJ, Chang RJ, DeFazio J, Meldrum DR, Judd HL: Origin of serum progestins in polycystic ovarian disease. Obstet Gynecol 1984; 64: 27.
20. MoltzL, Schvvartz U: Gonadal and adrenal androgen se-eretion in hirsute females. J Clin Endocrinol Metab 1986; 15: 229.
21. Azziz R, Boots LR, Parker CR Jr, Bradley E Jr, Zacur HA: 11 beta-hydroxylase deficieney in hyperandrogenism. Fertil Steril 1991; 55: 733.
22. Meikle AW, Wor!ey RJ, West CD: Adrenal corticoid hyperresponsiveness in hirsute vvomen. Fertil Steril 1984; 41: 575.
23. Erel CT, Senturk LM, Oral E, Colgar U, Ertungealp E: Adrenal androgenic response to 2-hour ACTH stimulation test in vvomen vvith PCOS. Gynecoi Endocrinol 1998; 12:223.
24. Kelcştimur F, Şahin Y, Ayata D, Tutuş A: The preva-lcncc of non-classic adrenal hyperplasia duc to llpV hydroxylase deficieney among hirsute vvomen in a Turk-ish population. Clin Endocrinol (Oxford) 1996; 45: 381.
25. Şahin Y, Keleştimur F: The frequency of late-onset 21-hydroxylasc and 11 bcta-hydroxylase deficieney in vvomen vvith polycystic ovary syndrome. Eur J Endocrinol 1997; İ37:670.
26. Keleştimur F, Şahin Y: Alternate pathvvay 17,20-lyase enzyme activity in the adrenals is enhanced in patients vvith polycystic ovary syndrome. Ferti! Steril 1999; 71: 1075.
27. Şahin Y, Ayata D, Keleştimur F: Lack of relationslıip betvveen 17-hydroxyprogesterone response to buserelin testing and hyperinsulinemia in polycystic ovary syndrome. Eur J Endocrinol 1997; 136:410.
28. Rosenfield RL, Barnes RB, Ehrmann DA: Studics of the naturc of İ7-hydroxyprogcslerone hyperresponsiveness to gonadotropin-relcasing hormone agonist challenge in funciional ovarian hyperandrogenism. J Clin Endocrinol Metab 1994; 79: 1686-92.

Thank you for copying data from http://www.arastirmax.com